Acer Therapeutics: Funding, Investors & Team (Nov 2026)
Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious rare, and life-threatening diseases with critical unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS). The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Acer Therapeutics has raised $49.5M across 2 funding rounds on record, the most recent an undisclosed round of $1.0M announced in Jun 2023.
That round is below the $8.8M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Acer Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2023.
Acer Therapeutics Funding Rounds
Acer Therapeutics raised $48.5M in a Post-IPO Debt announced in Mar 2022.
1.3 years later, an undisclosed round of $1.0M was announced in Jun 2023.
Acer Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Acer Therapeutics Funding Compared to Other Biotechnology Startups
Acer Therapeutics' latest round of $1.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Acer Therapeutics in Biotechnology and Newton
Companies Similar to Acer Therapeutics
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus…
Zafrens, a pharmaceutical research organization, focuses on designing life sciences solutions for…
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates to target driver oncogenes.…
Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…
100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…
MEND is a company focused on life sciences, determined to assist individuals in achieving better health…
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Acer Therapeutics Funding FAQs
What does Acer Therapeutics do?
Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious rare, and life-threatening diseases with critical unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS). The company was founded in 2013 and is headquartered in Newton, Massachusetts.
How much funding has Acer Therapeutics raised?
Acer Therapeutics has raised $49.5M across 2 rounds on record. The most recent is an undisclosed round of $1.0M announced in Jun 2023.
When did Acer Therapeutics last raise funding?
Acer Therapeutics' most recent funding round on record is an undisclosed round of $1.0M, announced in Jun 2023.
Who founded Acer Therapeutics?
FundedIQ lists Chris Schelling (Founder) at Acer Therapeutics.
Where is Acer Therapeutics headquartered?
Acer Therapeutics is based in Newton, Massachusetts, United States.
How many employees does Acer Therapeutics have?
Acer Therapeutics is in the 11-50 employee band.
How does Acer Therapeutics' funding compare to other Biotechnology startups?
Acer Therapeutics' latest round of $1.0M is below the $8.8M median round size for Biotechnology companies on FundedIQ across 4,188 tracked companies over the last two years.
About FundedIQ's Acer Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Acer Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.